Novo Nordisk bets $725M on heart-focused Corvidia—with the promise of $1.4B more – Fierce Biotech

Written by Amirah Al Idrus

Novo Nordisk plunked down $725 million for France’s Corvidia Therapeutics and its lead program, an anti-IL-6 antibody for the treatment of heart disease related to kidney disease. The Danish drugmaker aims to start a phase 3 study for the drug in 2021 and, if all goes well, Corvidia’s shareholders could ultimately cash out $2.1 billion.

The antibody, ziltikevimab, is in a phase 2b dose-finding trial to reduce the risk of heart problems in patients with chronic kidney disease who also have atherosclerosis, the buildup of fats, cholesterol and other substances in the artery walls. Having led six cardiovascular outcomes trials for its own medicines, like Victoza and Ozempic, which were both were developed for diabetes, Novo is prepared to move its new antibody into phase 3.

The deal is the biggest one that Mads Krogsgaard Thomsen, in his 20 years as Novo Nordisk’s chief science officer, has ever signed.

Read more here.

By Jessica Yap-Chung
Jessica Yap-Chung Profile Picture